SLNO Alert: Securities Fraud Lawsuit Filed – Act Now!

Introduction & Company Overview

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is a clinical-stage biopharmaceutical company that recently transitioned into commercial operations with its first product, VYKAT XR™ (diazoxide choline), approved in March 2025 for treating hyperphagia (insatiable hunger) in Prader–Willi syndrome (PWS) (www.nasdaq.com). This once-daily oral drug (formerly known as DCCR) is the first FDA-approved therapy specifically targeting the hallmark overeating behavior in PWS patients (seekingalpha.com) (www.nasdaq.com). The company’s fortunes are now highly concentrated in VYKAT XR’s success, as it has no other marketed products.

Despite a strong initial U.S. launch – with $66.0 million in net sales and even a quarterly profit of $26.0 million in Q3 2025 (www.globenewswire.com) – Soleno faces serious challenges. In early 2026, investors were jolted by news of a securities fraud class action lawsuit filed against the company, alleging that Soleno and its executives misled shareholders regarding safety risks of VYKAT XR and the drug’s true commercial outlook (www.prnewswire.com). This report provides a deep dive into SLNO’s current situation, covering its dividend policy, financial leverage, valuation, and – most critically – the risks, red flags, and open questions raised by recent events.

Dividend Policy & AFFO/FFO Considerations

No Dividend History: Soleno has never paid a dividend on its common stock and does not anticipate doing so in the foreseeable future (www.sec.gov) (www.sec.gov). Management has stated that all earnings and capital are reinvested to fund operations and growth, especially as the company only recently achieved its first commercial revenues. As a result, SLNO’s dividend yield is 0%, and any investor return will come solely from stock price appreciation (or depreciation).

AFFO/FFO Not Applicable: Metrics like Funds From Operations (FFO) or Adjusted FFO – typically used to evaluate REITs and other income-generating assets – are not relevant for Soleno. Soleno is a biotech company without recurring rental or asset income; it only just began generating product revenue in 2025. Traditional earnings metrics or cash burn rates are more appropriate for assessing Soleno’s performance than AFFO/FFO in this context.

Leverage, Debt Maturities & Coverage

Minimal Debt Load: Soleno historically financed its operations through equity raises rather than debt. As of the last reported balance sheet (end of 2022), the company had no traditional long-term debt – its liabilities consisted mainly of accounts payable, lease obligations, warrants, and a contingent earnout liability from a past acquisition (www.sec.gov). In fact, Soleno’s total liabilities were only ~$16 million against $26.5 million in assets at that time (www.sec.gov), reflecting a low-leverage balance sheet.

URGENT: Get “Trump\'s Secret Fund” — Learn How to Collect Royalty Checks

Limited report reveals the #1 American oil & gas royalty play that can start paying monthly — with just $50.

Mobile-friendly
Start w/ $50

Yes — Send My Report
Fast download • Instant access • Seats limited

Cash Infusions Instead of Debt: To fund the pivotal trial and product launch, Soleno tapped equity markets. It raised $13.8 million in a March 2022 offering (www.sec.gov) and later secured a much larger capital raise in 2025. In July 2025, following FDA approval, Soleno completed an underwritten stock offering of $230 million gross (www.globenewswire.com). This massive cash infusion brought its cash reserves to $556.1 million by Q3 2025 (www.globenewswire.com). With over half a billion dollars in cash and no bank debt, Soleno currently carries net cash on its balance sheet – a strong buffer for ongoing needs. The absence of interest-bearing debt means traditional coverage ratios (e.g. interest coverage) are a non-issue; in fact, Soleno likely earns interest income on its large cash position, further bolstering short-term liquidity.

Debt Maturities & Obligations: Since Soleno has no bonds or loans outstanding, there are no looming debt maturities to worry about. However, one key long-term obligation is the contingent earnout from its 2017 acquisition of Essentialis, the company that originated DCCR. Soleno owes up to $21.2 million in milestone payments to Essentialis’s former owners if VYKAT XR meets certain sales targets (www.sec.gov) (www.sec.gov). Specifically, two milestones were defined at $100 million and $200 million in cumulative revenues (www.sec.gov). Soleno has accrued an estimated $8.8 million as a liability for those earnouts (probability-weighted) (www.sec.gov). Given VYKAT XR’s fast start – $66M in one quarter – the first $100M sales milestone could be reached soon, triggering a substantial cash payout. The company’s ample cash reserves should cover this, but it’s an upcoming use of cash to monitor. Other commitments (like operating leases) are minor by comparison.

Coverage Ratios: With no debt or interest expense, interest coverage is moot – Soleno doesn’t need operating earnings to service debt at this time. Instead, the more relevant “coverage” consideration is whether Soleno’s cash on hand can cover its operational cash burn until the business becomes self-sustaining. Before approval, Soleno was burning ~$20+ million per year in R&D and overhead (www.sec.gov) (www.sec.gov), raising going-concern flags. Now, with product sales and profit in Q3 2025, the equation has changed. If VYKAT XR’s revenues hold up, Soleno may generate operating cash rather than consume it – a dramatic improvement in coverage of its expenses. However, if sales falter (see Risks section), the company might again need to draw down cash or raise funds in the future. For now, Soleno’s large cash cushion provides several years of runway even under adverse scenarios, making near-term liquidity risk low.

Valuation and Financial Metrics

Market Capitalization & Cash-Adjusted Value: Following the 2025 approval and financing, Soleno’s share count increased (the July 2025 equity offering added roughly 4–5 million shares). By early 2026, the stock has been trading in the $45–$60 range (finance.yahoo.com). At ~$50 per share, market capitalization is on the order of $750 million (assuming ~15 million shares outstanding post-raise). However, with over $550 million in cash on the balance sheet, Soleno’s enterprise value (EV) is significantly lower – roughly $200 million using the above figures. This means the market is valuing the entire VYKAT XR franchise and pipeline at only ~$200M beyond the cash, reflecting either a potentially undervalued situation or substantial perceived risks (or both).

Earnings and Price/Earnings (P/E): Notably, Soleno achieved positive earnings in Q3 2025 due to the strong launch quarter. Net income was $26.0 million for Q3 (www.globenewswire.com), which equates to roughly $1.73 earnings per share for that quarter alone (assuming ~15M shares). Annualizing that single quarter would imply a forward P/E ratio in the mid-single digits. However, such an extrapolation is risky – initial launch quarters can include boluses of pent-up demand (and revenue recognition of initial channel fill). It is unclear if Soleno can maintain or grow that profit level given subsequent headwinds. If VYKAT XR’s uptake were sustained and safety concerns mitigated, Soleno might appear extremely cheap on a P/E basis. For instance, even at a $750M market cap, a hypothetical $100M/year net income would be a P/E of 7.5×. This low multiple suggests investors are skeptical that current earnings are reliable or that growth will continue, likely due to the emerging safety and legal issues.

Revenue Multiples: On a price-to-sales basis, Soleno’s valuation is also modest for a high-margin orphan drug company. Q3’s $66M revenue implies a run-rate of ~$264M annually. Against an EV of ~$200M, the EV/Sales ratio might be well below 1× (around 0.8× of annualized Q3 sales). For context, successful rare-disease biotech peers often trade at multiples of 4–8× sales in anticipation of growth and strong margins. The subdued EV/Sales here again indicates that the market is pricing in a significant probability of setback – such as plateauing sales, costly issues, or even product withdrawal. If VYKAT’s trajectory is truly “game-changing” and safety issues prove manageable, there could be substantial upside. Conversely, if the bearish scenario materializes (sales collapse or heavy costs to address safety), the current valuation may be justified or still too high.

Comparables: Direct comparables for Soleno are limited, given PWS had no prior therapies. That said, competitors are on the horizon. For example, several companies are developing rival treatments for hyperphagia in PWS (e.g., Intranasal carbetocin, Livoletide (AZP-531), RM-853, etc.) (pmc.ncbi.nlm.nih.gov). None have reached the market yet, but their progress will affect how Soleno is valued relative to future competition. Investors should also compare Soleno’s valuation to other single-product orphan drug companies of similar scale. Until recently, Soleno’s profile resembled a small-cap clinical-stage biotech (valued mostly on probability of approval); now it must be viewed as a commercial-stage pharma with a mix of growth potential and liability risks.

Risks and Red Flags

Soleno faces serious risks that have only recently come to light, which partly explains the class action lawsuit and discounted valuation. Key red flags include:

– Safety Concerns – Fluid Retention and Adverse Events: According to the lawsuit, Soleno’s Phase 3 program for DCCR (VYKAT XR) “systematically downplayed or concealed significant evidence of safety concerns”, particularly excess fluid retention observed in clinical trial participants (www.prnewswire.com). Excess fluid retention can lead to edema, heart strain, and other complications – a worrying side effect in PWS patients who often have complex medical issues. The implication is that Soleno knew of these issues but did not fully disclose their severity. Supporting this, real-world data has been troubling: On September 10, 2025, Soleno disclosed a patient death linked to VYKAT XR, which caused the stock to drop over 12% in one day (www.businesswire.com). It’s unclear if fluid retention contributed to the death, but the incident validates the presence of serious safety risks. Earlier, on August 15, 2025, short-seller Scorpion Capital published a critical report alleging VYKAT XR poses serious safety hazards and might even face withdrawal from the market, sending the stock down ~8% (www.businesswire.com). These developments suggest that safety red flags are not just theoretical – they are manifesting in patient outcomes. An FDA-mandated black-box warning or additional monitoring for VYKAT XR is a distinct possibility if further data confirm risks. The worst-case scenario, though still remote, would be regulatory suspension or recall of the drug if benefits no longer outweigh risks.

– Allegations of Misrepresentation (Securities Fraud Claims): The class action lawsuit (filed March 2026) alleges that Soleno made false or misleading statements and omitted material facts about the safety and commercial viability of VYKAT XR (www.prnewswire.com). Specifically, the suit claims Soleno knew about the fluid-retention problems and associated safety risks but “systematically misrepresented” them to investors (www.prnewswire.com). It also asserts that Soleno failed to disclose that these safety issues could severely limit the drug’s adoption and commercial success – via higher discontinuation rates, doctors’ reluctance to prescribe, and the potential need for regulatory action (www.prnewswire.com). If these allegations are proven, it indicates serious management credibility issues and potential wrongdoing. Even if not proven in court, the mere accusation can damage investor trust. It’s worth noting that multiple law firms are now involved (Rosen Law, Robbins Geller, Gibbs Law, etc.), which often occurs if shareholders experienced large losses. The class period defined is March 26, 2025 (the approval date) through November 4, 2025 (www.prnewswire.com), suggesting the suit centers on statements made during the drug’s launch phase.

– Impact on Commercial Trajectory: The unfolding safety controversy has already disrupted Soleno’s business. By the company’s own admission, the Scorpion Capital report and ensuing negative publicity have had a chilling effect on VYKAT XR’s launch. In the Q3 2025 update, Soleno management noted that starting in mid-August (after the short-seller report), they saw a “disruption” in the drug’s trajectory: fewer new patient start forms and higher discontinuation rates as some patients stopped treatment (www.globenewswire.com). In other words, the PWS patient community and physicians became alarmed, likely due to the safety warnings swirling around. This is a critical red flag – it indicates that even if the drug is effective, trust has been eroded. If prescribers are hesitating and patients are quitting therapy, future sales may suffer. Indeed, Soleno’s Q4 2025 or early 2026 performance may show whether growth stalled after that initial pent-up demand was met. The momentum loss could be hard to reverse without clear evidence to refute the safety concerns.

– Single-Product Dependence: Soleno is essentially a “one-product company” now. This concentration amplifies risk: any hurdle for VYKAT XR (be it safety, competition, manufacturing, or regulatory) directly threatens the company’s entire revenue stream. There is no diversification to cushion against a VYKAT XR setback. Soleno does not pay a dividend or have other stable cash flows to fall back on, so a collapse in VYKAT XR sales would rapidly deplete the cash reserves (especially after the earnout payments). Investors must recognize this binary risk profile: success hinges on one drug’s fortunes.

– Insider Actions and Governance: While not explicitly highlighted in public sources, a prudent investor will consider whether insiders sold stock during the class period (after approval but before news of problems). Significant insider selling could be a red flag if it occurred prior to the safety revelations. Additionally, the handling of the safety data raises governance questions: Did the clinical and regulatory teams fully brief the FDA on fluid-retention incidents? If any lack of transparency to regulators is uncovered, it could provoke regulatory penalties or stricter oversight. The lawsuit and short report also criticize Soleno’s pricing (“price-gouging scheme” was mentioned) (www.globenewswire.com), which hints at reputational risk in how the company balances profit vs. patient welfare. All these factors imply that scrutiny on Soleno’s management is intensifying.

– Potential Legal and Financial Fallout: The securities lawsuit is in early stages, but it creates an overhang. Defending such litigation will consume management time and legal expenses (though likely covered partly by D&O insurance). If Soleno were to lose in court or agree to a settlement, the financial cost could be substantial (possibly in the tens of millions, depending on damages). Moreover, if evidence shows knowing misconduct, executives could face consequences and the company’s leadership might need a refresh to restore credibility. Separately, if patient lawsuits arise (e.g. from families of any patients harmed by VYKAT XR), that’s another layer of legal risk. With ~$550M cash, Soleno can withstand some payouts, but these issues could slow down reinvestment in the business or even force changes in how the drug is marketed.

In summary, Soleno’s risk profile has greatly increased in the wake of the safety issues and fraud allegations. Once seen as a promising rare-disease play, the company now carries a cloud of uncertainty. The key red flag is that the very attributes that made VYKAT XR a potential “game-changer” – its novel mechanism and rapid uptake – are now double-edged swords due to unexpected side effects. Investors should monitor safety data closely, as the balance of efficacy vs. risk will determine VYKAT’s ultimate viability.

Open Questions & Uncertainties

Given the fluid situation (no pun intended), several open questions remain unanswered about SLNO’s future:

– Can Safety Concerns Be Mitigated? What steps will Soleno take to address the fluid retention and related safety issues? It’s unclear if a risk mitigation strategy (e.g. diuretic co-therapy, stricter patient monitoring, lower dosing in certain populations) could alleviate the problem. Will the FDA require special precautions or labeling changes for VYKAT XR after reviewing post-market data? The ability to manage these side effects will directly impact patient and physician confidence.

– Will VYKAT XR’s Adoption Rebound or Stall? After the initial surge of over 1,000 patient sign-ups, demand appeared to slow due to the negative publicity (www.globenewswire.com). The big question is whether this is a temporary blip or a lasting dampener. PWS patients and caregivers might take a “wait and see” approach now. Q4 2025 and Q1 2026 sales figures will be telling: a continued upward sales trend would indicate the drug’s benefits outweigh concerns for many, whereas a plateau or decline would signal lingering reluctance. Soleno’s assertion of a “compelling…safety profile” in Q3 (www.globenewswire.com) sounds optimistic against recent events – can they back this claim with data (for example, by demonstrating that the patient death was unrelated to the drug, or that discontinuation rates are improving)? This remains to be seen.

– How Will the Lawsuit Play Out? The class action is in early days – the lead plaintiff process is underway (deadline May 5, 2026) (www.prnewswire.com). It could be years before a resolution, but important milestones (motion to dismiss, discovery disclosures) could bring new information to light. One open question is what internal documents might show. If emails or trial records reveal that Soleno’s execs were aware of severe side effects and chose to soft-pedal them, it would hugely damage the company’s defense (and credibility). Conversely, if Soleno can show it acted responsibly and the adverse events were unfortunate but not predictable at approval, they may fend off the worst of the claims. Investors will want to keep an eye on any settlement talks – an early settlement might indicate the company prefers to avoid airing details publicly (which could itself be a red flag), whereas a vigorous defense might mean they believe the claims are exaggerated.

– What is the Long-Term Commercial Outlook? Even assuming VYKAT XR remains on the market, how big can it get in the face of these safety concerns? The total PWS market (all ages) was estimated around $2.1 billion in 2018 (seekingalpha.com), but that was before any treatment existed. With VYKAT XR indicated for ages 4 and up, Soleno initially aimed to capture a large portion of eligible patients over time. Now, with a black cloud over safety, the peak penetration may be lower than initially hoped. Will physicians restrict use to only the most severe cases? Will some families opt to stick with strict behavioral/diet control rather than try the drug? These factors could limit revenue growth. Additionally, Soleno’s earlier claim of a “compelling efficacy and safety profile” (www.globenewswire.com) will be under the microscope – they will need to update investors if real-world data diverges from clinical trial results. An open question is whether additional studies will be needed (or voluntarily undertaken) to further assess safety – for instance, a post-marketing study focusing on long-term cardiovascular outcomes in VYKAT XR patients. Such studies could be costly but might be necessary to rebuild confidence.

– Will Competitors Capitalize? The window of opportunity for Soleno may narrow if competitors accelerate their programs. At least five potential rival therapies for hyperphagia in PWS are in development (www.delveinsight.com). If Soleno falters, competitors (perhaps touting different mechanisms or better safety) could gain favor. One open question: Might a competitor’s drug even overtake VYKAT XR as the preferred treatment? It’s too early to tell, but investors should watch clinical readouts from other PWS trials in 2026–2027. Ironically, the controversy around VYKAT might embolden some competitors to position their drug as the “safer” alternative. Soleno’s time to establish VYKAT XR as the standard could be limited; thus, how it navigates the next year is critical.

– Can Soleno Leverage its Cash for Strategic Moves? With over $500M in cash, Soleno has a war chest. An open question is how they will use it. They could invest in further R&D (perhaps diversify beyond PWS to reduce single-drug risk), acquire complementary assets, or even consider partnering the drug in markets outside the U.S. A strategic partnership for Europe or other regions might both validate the drug and share the burden of safety monitoring. Alternatively, might a larger pharma see Soleno as an acquisition target, given PWS is a rare disease market? Typically, big pharma would shy away until uncertainties clear, but Soleno’s cash and asset could be attractive at some price. Management’s decisions on capital allocation – hunkering down to focus solely on VYKAT, or broadening the portfolio – remain to be seen.

– How Will Patient and Advocate Perception Evolve? PWS is a tight-knit rare disease community. Advocacy groups and caregivers initially hailed VYKAT XR’s approval as a breakthrough (finally, a drug to address the relentless hunger). The Drug Discovery News even called it a “game-changer” for PWS (www.drugdiscoverynews.com). However, safety scares can quickly alter sentiment. An open question is whether Soleno can regain the community’s trust. Transparent communication will be key – e.g., publishing full safety data, working closely with PWS organizations, and possibly setting up patient support programs to manage side effects. If families feel the company is putting profits over patient welfare (as the “price-gouging” critique suggests (www.globenewswire.com)), goodwill could evaporate. On the flip side, if many patients experience life-changing benefits (weight stabilization, improved behavior) without serious issues, positive word-of-mouth could still make VYKAT XR a success. The anecdotal reports and quality-of-life outcomes emerging over the next few quarters will be crucial data points beyond the spreadsheets.

In conclusion, Soleno Therapeutics is at a crossroads. The company achieved what it set out to do – bring a first-in-class PWS drug to market – and even demonstrated it can be profitable. Yet, the unfolding safety and legal saga threatens to undermine that achievement. Investors must weigh the upside of a pioneering rare disease therapy (with strong initial demand and significant cash reserves backing it) against the downside of potential safety failures, legal liabilities, and loss of confidence. The coming months will likely bring more clarity on whether VYKAT XR can overcome its setbacks or if SLNO will be a cautionary tale of a biotech whose red flags were not heeded in time.

Sources: The information above is grounded in Soleno’s SEC filings, investor communications, and reputable financial news. Notably, Soleno’s 10-K confirms the lack of any dividend historically (www.sec.gov), and its Q3 2025 earnings release highlights the initial commercial success and cash raise (www.globenewswire.com) (www.globenewswire.com). The emerging safety concerns and lawsuit allegations are documented through multiple first-hand sources: a Business Wire report of the patient death and short-seller claims (www.businesswire.com), and the Rosen Law press release detailing the class action allegations of misrepresentation (www.prnewswire.com) (www.prnewswire.com). These issues, along with Soleno management’s own disclosures of a launch “disruption” post-Scorpion report (www.globenewswire.com), form the basis of the risk analysis. Investors should review these filings and news releases (cited in-line) for a deeper understanding and remain alert to further updates in this rapidly evolving situation.

For informational purposes only; not investment advice.